Since Pradaxa was made available, a prescription anticoagulant that was released in 2010, concern over its use and adverse health effects has continued to grow. In fact, Pradaxa has become the subject of several lawsuits, while litigation surrounding the drug continues to increase.
Pradaxa, a new anticoagulant, is designed to stop a series of chemical reactions that lead to blood clotting. Unfortunately, Pradaxa has no “antidote” or reversal agent — as do other anticoagulants — that would shut off this reaction. As a result, patients are left without any way to reverse Pradaxa’s effects in health emergencies. In addition, patients have been having serious and even fatal adverse reactions in numbers far higher than Pradaxa’s manufacturer reported would be expected.
Pradaxa (Dabigatran) is an oral anticoagulant that was approved by the FDA in 2010. Pradaxa is from the class of direct thrombin inhibitors and it is manufactured by Boehringer Ingelheim, a German pharmaceutical company, and is sold as an alternative to Warfarin.
On August 8, 2012MDL 2385 was created before the United States District Court Southern District of Illinois [In Re: Pradaxa 3:12-md-2385-DRH-SCW]. The bellwether trials for the Pradaxa lawsuits will be held on August 11, 2014; September 22, 2014; November 3, 2014; January 5, 2015; and February 16, 2015.
If you or a loved one has suffered ill effects because of Pradaxa, call us at 818-991-8900 or contact us online to set up a time to talk with our team about your injuries.